secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2026-08-06T20:09:28+00:00
Accession:  0001437749-26-026262
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q2 revenue $13.9M (+22% YoY); Surgical Aesthetics up 28%; reaffirms FY guidance
--------------------------------------------------------------------------------

- Total revenue $13.9M vs $11.4M in Q2 2025; Surgical Aesthetics segment grew 28% to $12.4M.
- Net loss narrowed to $3.2M ($0.07/sh) from $3.8M ($0.09/sh); Adjusted EBITDA loss improved to $0.7M from $2.0M.
- Reaffirmed FY2026 revenue guidance $59.0M-$60.0M; Surgical Aesthetics expected $54.0M-$55.0M.
- Limited commercial launch of power liposuction handpiece for AYON platform began in June 2026 after FDA clearance.
- Cash and equivalents $27.6M; management expects to yield cash through 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774926026262/0001437749-26-026262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774926026262/apyx20260602_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-026262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer